Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient ...
Under the terms of the agreement, OPKO will accept 60% of the development costs, while Entera will shoulder 40%.
Produced by the German company Boehringer Ingelheim, alongside Zealand Pharma, Survodutide is an injectable drug that activates both the glucagon and GLP-1 receptors. According to Nature, the drug is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback